10 Jan 2023 ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank Member news
09 Jan 2023 Foundational RNA and cLNP expert Antonin (Tony) de Fougerolles joins eTheRNA as independent board member Member news
06 Jan 2023 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Member news
23 Dec 2021 Peter Scheyltjens (52), CEO en oprichter van de Advipro Groep, geeft de fakkel door aan zijn rechterhand Toon Witvrouwen (35) Member news
20 Dec 2021 Biotalys and Biobest enter into strategic partnership to expand reach of novel biocontrol solutions Member news
20 Dec 2021 argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Member news
10 Dec 2021 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
